Dare Bioscience Inc (DARE)

$1.84 +0.06 (3.37%)
Market Cap 25.43M
Revenue (ttm) 10,000.00
Net Income (ttm) -4.05M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -40,500.00%
Debt to Equity Ratio 0.00
Volume 81,100
Avg Vol 137,626
Day's Range N/A - N/A
Shares Out 14.29M
Stochastic %K 64%
Beta 0.77
Analysts Strong Sell
Price Target $10.75

Company Profile

Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis. It also develops Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia for the treatment of female sexual aro...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 926 7655
Address:
3655 Nobel Drive, Suite 260, San Diego, United States
HMIC
HMIC Dec. 8 at 3:23 AM
$DARE
0 · Reply
JarvisFlow
JarvisFlow Dec. 2 at 11:56 AM
HC Wainwright & Co. has adjusted their stance on Dare Bioscience ( $DARE ), setting the rating to Buy with a target price of 12.
0 · Reply
TravisA9
TravisA9 Dec. 2 at 12:15 AM
$DARE “We will have maximum strategic flexibility” -Sabrina Very good chance this company is an actual $0 now. Over the past 2 years, I have written extensively on why I feel this is accurate . Feel sorry for people who listened to the sheep on Stocktwits and Sabrina. https://ir.darebioscience.com/news-releases/news-release-details/dare-bioscience-announces-return-rights-ovaprener-phase-3
0 · Reply
BuyAndHoldStocks
BuyAndHoldStocks Dec. 1 at 5:42 PM
$DARE What a poor rating of Ovarprene's potential from Bayer. No wonder Dare was tight-lipped about Ovarprene at the latest CC and milestones were absent from their company presentation. There have certainly been talks with Bayer since this summer. The risk in the company has increased. IMO
1 · Reply
GolfPro999
GolfPro999 Dec. 1 at 3:56 PM
$DARE great news today getting the rights back for Ovaprene. 📈 positioned for buyout now.
1 · Reply
UniversalTrading
UniversalTrading Nov. 28 at 12:41 PM
$DARE True .. Shares Ownership - Insiders = 0.97% !! Not even 1% .. Shows you how much they value and believe in their own Company and future doesn't it!! One of the worst Positions I have ever entered. Thank goodness it's only a small Investment! Been here for months and Red since day 1 !! Purely curious as to what f**kery will transpire!!
0 · Reply
zhusjason1
zhusjason1 Nov. 26 at 5:08 PM
$DARE as someone who’s mentioned that insiders never bought this fking 💩 hole , how can it inspire investors to buy more?
0 · Reply
Djdanny
Djdanny Nov. 26 at 3:48 PM
$DARE Unfortunately not here
0 · Reply
Djdanny
Djdanny Nov. 24 at 4:04 PM
$DARE No volume .🤮
0 · Reply
prasan2015
prasan2015 Nov. 24 at 2:08 PM
$DARE could pop here
0 · Reply
Latest News on DARE
Daré Bioscience, Inc. (DARE) Discusses DARE to PLAY Sildenafil Cream as a Treatment Option for Female Genital Arousal Concerns Transcript

Nov 22, 2025, 7:23 AM EST - 16 days ago

Daré Bioscience, Inc. (DARE) Discusses DARE to PLAY Sildenafil Cream as a Treatment Option for Female Genital Arousal Concerns Transcript

Daré Bioscience, Inc. (DARE) Q3 2025 Earnings Call Transcript

Nov 13, 2025, 7:41 PM EST - 24 days ago

Daré Bioscience, Inc. (DARE) Q3 2025 Earnings Call Transcript

Daré Bioscience Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 13, 2025, 4:01 PM EST - 25 days ago

Daré Bioscience Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Daré Bioscience to Host Third Quarter 2025 Financial Results and Company Update Conference Call and Webcast on November 13, 2025

Nov 6, 2025, 8:00 AM EST - 4 weeks ago

Daré Bioscience to Host Third Quarter 2025 Financial Results and Company Update Conference Call and Webcast on November 13, 2025

Daré Bioscience to Receive up to $499,000 to Support Preeclampsia Research

Sep 24, 2025, 8:00 AM EDT - 2 months ago

Daré Bioscience to Receive up to $499,000 to Support Preeclampsia Research

Daré Bioscience, Inc. (DARE) Q2 2025 Earnings Call Transcript

Aug 14, 2025, 7:48 PM EDT - 4 months ago

Daré Bioscience, Inc. (DARE) Q2 2025 Earnings Call Transcript

Daré Bioscience Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 14, 2025, 4:01 PM EDT - 4 months ago

Daré Bioscience Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Daré Bioscience to Host Second Quarter 2025 Financial Results and Company Update Conference Call and Webcast on August 14, 2025

Aug 7, 2025, 8:00 AM EDT - 4 months ago

Daré Bioscience to Host Second Quarter 2025 Financial Results and Company Update Conference Call and Webcast on August 14, 2025

Daré Bioscience and Rosy Wellness Launch First Phase of Patient-Focused Campaign to Support DARE to PLAY™ Sildenafil Cream

Jul 29, 2025, 8:00 AM EDT - 4 months ago

Daré Bioscience and Rosy Wellness Launch First Phase of Patient-Focused Campaign to Support DARE to PLAY™ Sildenafil Cream

UPDATE - Daré Bioscience to Host August 6 Webinar: The DARE to PLAY™ Difference - The Sildenafil Cream That Raises the Bar

Jul 21, 2025, 1:47 PM EDT - 5 months ago

UPDATE - Daré Bioscience to Host August 6 Webinar: The DARE to PLAY™ Difference - The Sildenafil Cream That Raises the Bar

Crude Oil Moves Lower; Daré Bioscience Shares Jump

Jul 14, 2025, 1:09 PM EDT - 5 months ago

Crude Oil Moves Lower; Daré Bioscience Shares Jump

Positive Interim Phase 3 Results Highlight Potential of Ovaprene®, Novel Hormone-Free Contraceptive

Jul 14, 2025, 8:00 AM EDT - 5 months ago

Positive Interim Phase 3 Results Highlight Potential of Ovaprene®, Novel Hormone-Free Contraceptive

Daré Bioscience Receives $6 Million Non-Dilutive Grant Installment; $37.8M to Date of up to $49M Commitment Supporting Smart Drug Delivery Device for Contraception; Platform has Broader Application Potential in Obesity and Metabolic Disorders

Jul 11, 2025, 8:00 AM EDT - 5 months ago

Daré Bioscience Receives $6 Million Non-Dilutive Grant Installment; $37.8M to Date of up to $49M Commitment Supporting Smart Drug Delivery Device for Contraception; Platform has Broader Application Potential in Obesity and Metabolic Disorders

Daré Bioscience Announces Adjournment of Annual Meeting of Stockholders

Jun 12, 2025, 5:00 PM EDT - 6 months ago

Daré Bioscience Announces Adjournment of Annual Meeting of Stockholders

Daré Bioscience, Inc. (DARE) Q1 2025 Earnings Call Transcript

May 13, 2025, 11:13 PM EDT - 7 months ago

Daré Bioscience, Inc. (DARE) Q1 2025 Earnings Call Transcript

Daré Bioscience Reports First Quarter 2025 Financial Results and Provides Company Update

May 13, 2025, 4:01 PM EDT - 7 months ago

Daré Bioscience Reports First Quarter 2025 Financial Results and Provides Company Update

Daré Bioscience, Inc. (DARE) Q4 2024 Earnings Call Transcript

Mar 31, 2025, 10:14 PM EDT - 8 months ago

Daré Bioscience, Inc. (DARE) Q4 2024 Earnings Call Transcript

Daré Bioscience Reports Full Year 2024 Financial Results and Provides Company Update

Mar 31, 2025, 4:01 PM EDT - 9 months ago

Daré Bioscience Reports Full Year 2024 Financial Results and Provides Company Update

Daré Bioscience to Host Full Year 2024 Financial Results and Company Update Conference Call and Webcast on March 31, 2025

Mar 24, 2025, 8:00 AM EDT - 9 months ago

Daré Bioscience to Host Full Year 2024 Financial Results and Company Update Conference Call and Webcast on March 31, 2025

Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to Support DARE-HPV Development

Feb 6, 2025, 8:00 AM EST - 10 months ago

Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to Support DARE-HPV Development

Daré Bioscience to Participate in the Women's Health Series at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 9, 2025, 8:00 AM EST - 11 months ago

Daré Bioscience to Participate in the Women's Health Series at the 43rd Annual J.P. Morgan Healthcare Conference

Daré Bioscience, Inc. (DARE) Q3 2024 Earnings Call Transcript

Nov 14, 2024, 8:03 PM EST - 1 year ago

Daré Bioscience, Inc. (DARE) Q3 2024 Earnings Call Transcript

Daré Bioscience Reports Third Quarter 2024 Financial Results and Provides Company Update

Nov 14, 2024, 4:01 PM EST - 1 year ago

Daré Bioscience Reports Third Quarter 2024 Financial Results and Provides Company Update

Daré Bioscience to Host Third Quarter 2024 Financial Results and Company Update Conference Call and Webcast on November 14, 2024

Nov 7, 2024, 8:00 AM EST - 1 year ago

Daré Bioscience to Host Third Quarter 2024 Financial Results and Company Update Conference Call and Webcast on November 14, 2024

Daré Bioscience Selected to Receive $10 Million Award from ARPA-H's Sprint for Women's Health

Oct 23, 2024, 12:30 PM EDT - 1 year ago

Daré Bioscience Selected to Receive $10 Million Award from ARPA-H's Sprint for Women's Health

Daré Bioscience Announces Common Stock Purchase Agreement for up to $15 Million with Lincoln Park Capital Fund, LLC

Oct 21, 2024, 8:05 AM EDT - 1 year ago

Daré Bioscience Announces Common Stock Purchase Agreement for up to $15 Million with Lincoln Park Capital Fund, LLC

Daré Bioscience, Inc. (DARE) Q2 2024 Earnings Call Transcript

Aug 12, 2024, 8:40 PM EDT - 1 year ago

Daré Bioscience, Inc. (DARE) Q2 2024 Earnings Call Transcript

Daré Bioscience Reports Second Quarter 2024 Financial Results and Provides Company Update

Aug 12, 2024, 4:01 PM EDT - 1 year ago

Daré Bioscience Reports Second Quarter 2024 Financial Results and Provides Company Update

Daré Bioscience Regains Compliance with Nasdaq Minimum Bid Price Rule

Jul 19, 2024, 8:00 AM EDT - 1 year ago

Daré Bioscience Regains Compliance with Nasdaq Minimum Bid Price Rule

Biotech Executive Lisa Walters-Hoffert Joins Kiora Pharmaceuticals' Board of Directors

Jul 1, 2024, 6:54 AM EDT - 1 year ago

Biotech Executive Lisa Walters-Hoffert Joins Kiora Pharmaceuticals' Board of Directors

KPRX

Daré Bioscience Announces Reverse Stock Split

Jun 27, 2024, 8:00 AM EDT - 1 year ago

Daré Bioscience Announces Reverse Stock Split

Daré Bioscience, Inc. (DARE) Q1 2024 Earnings Call Transcript

May 14, 2024, 6:30 PM EDT - 1 year ago

Daré Bioscience, Inc. (DARE) Q1 2024 Earnings Call Transcript

Daré Bioscience Reports First Quarter 2024 Financial Results and Provides Company Update

May 14, 2024, 8:00 AM EDT - 1 year ago

Daré Bioscience Reports First Quarter 2024 Financial Results and Provides Company Update

Daré Bioscience Selected as a Member of ARPA-H Investor Catalyst Hub Spoke Network

May 2, 2024, 8:00 AM EDT - 1 year ago

Daré Bioscience Selected as a Member of ARPA-H Investor Catalyst Hub Spoke Network

Daré Bioscience Secures $22 Million in Non-Dilutive Strategic Royalty Financing to Advance Phase 3 First-in-Category Women's Health Product Candidates through Key Catalysts

Apr 30, 2024, 7:30 AM EDT - 1 year ago

Daré Bioscience Secures $22 Million in Non-Dilutive Strategic Royalty Financing to Advance Phase 3 First-in-Category Women's Health Product Candidates through Key Catalysts

Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1

Apr 23, 2024, 8:00 AM EDT - 1 year ago

Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1

Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from a Pre-Pivotal Postcoital Test Study of Ovaprene®: an Investigational Hormone-Free Monthly Intravaginal Contraceptive

Apr 11, 2024, 8:00 AM EDT - 1 year ago

Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from a Pre-Pivotal Postcoital Test Study of Ovaprene®: an Investigational Hormone-Free Monthly Intravaginal Contraceptive

Daré Bioscience, Inc. (DARE) Q4 2023 Earnings Call Transcript

Mar 28, 2024, 8:47 PM EDT - 1 year ago

Daré Bioscience, Inc. (DARE) Q4 2023 Earnings Call Transcript

Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company Update

Mar 28, 2024, 8:00 AM EDT - 1 year ago

Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company Update

Daré Bioscience to Host Full Year 2023 Financial Results and Company Update Conference Call and Webcast on March 28, 2024

Mar 21, 2024, 8:00 AM EDT - 1 year ago

Daré Bioscience to Host Full Year 2023 Financial Results and Company Update Conference Call and Webcast on March 28, 2024

This overlooked corner of women's health could be a $350 billion market opportunity

Mar 15, 2024, 2:33 PM EDT - 1 year ago

This overlooked corner of women's health could be a $350 billion market opportunity

PFE PGNY VTGN BTMD

Daré Bioscience Announces Positive End-of-Phase 2 Meeting with FDA on Development of Sildenafil Cream, 3.6% in Female Sexual Arousal Disorder and Provides Company Focus Areas for 2024

Jan 31, 2024, 8:00 AM EST - 2 years ago

Daré Bioscience Announces Positive End-of-Phase 2 Meeting with FDA on Development of Sildenafil Cream, 3.6% in Female Sexual Arousal Disorder and Provides Company Focus Areas for 2024

Daré Bioscience Announces Executive Team and Board of Directors Changes

Jan 26, 2024, 4:30 PM EST - 2 years ago

Daré Bioscience Announces Executive Team and Board of Directors Changes

Daré Bioscience Announces Grant to Support Biotherapeutic Product Development

Jan 17, 2024, 8:00 AM EST - 2 years ago

Daré Bioscience Announces Grant to Support Biotherapeutic Product Development

Daré Bioscience's DARE-LARC1 Platform Technology Achieves Proof-of-Concept Device that has Transformative Potential for Women's Health as well as in Treating a Broad Range of Diseases

Jan 4, 2024, 8:00 AM EST - 2 years ago

Daré Bioscience's DARE-LARC1 Platform Technology Achieves Proof-of-Concept Device that has Transformative Potential for Women's Health as well as in Treating a Broad Range of Diseases

Daré Bioscience Secures $12 million in Royalty-backed Investment Structure

Dec 26, 2023, 8:00 AM EST - 2 years ago

Daré Bioscience Secures $12 million in Royalty-backed Investment Structure

Daré Bioscience Announces Positive Topline Pharmacokinetic and Exploratory Efficacy Results from the DARE-PDM1 Phase 1 Clinical Study

Dec 20, 2023, 8:00 AM EST - 2 years ago

Daré Bioscience Announces Positive Topline Pharmacokinetic and Exploratory Efficacy Results from the DARE-PDM1 Phase 1 Clinical Study

Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) to Support DARE-PTB1 Phase 1 Human Clinical Study

Dec 13, 2023, 8:00 AM EST - 2 years ago

Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) to Support DARE-PTB1 Phase 1 Human Clinical Study

Daré Bioscience, Inc. (DARE) Q3 2023 Earnings Call Transcript

Nov 9, 2023, 9:56 PM EST - 2 years ago

Daré Bioscience, Inc. (DARE) Q3 2023 Earnings Call Transcript

Daré Bioscience Reports Third Quarter 2023 Financial Results and Provides Company Update

Nov 9, 2023, 8:00 AM EST - 2 years ago

Daré Bioscience Reports Third Quarter 2023 Financial Results and Provides Company Update

HMIC
HMIC Dec. 8 at 3:23 AM
$DARE
0 · Reply
JarvisFlow
JarvisFlow Dec. 2 at 11:56 AM
HC Wainwright & Co. has adjusted their stance on Dare Bioscience ( $DARE ), setting the rating to Buy with a target price of 12.
0 · Reply
TravisA9
TravisA9 Dec. 2 at 12:15 AM
$DARE “We will have maximum strategic flexibility” -Sabrina Very good chance this company is an actual $0 now. Over the past 2 years, I have written extensively on why I feel this is accurate . Feel sorry for people who listened to the sheep on Stocktwits and Sabrina. https://ir.darebioscience.com/news-releases/news-release-details/dare-bioscience-announces-return-rights-ovaprener-phase-3
0 · Reply
BuyAndHoldStocks
BuyAndHoldStocks Dec. 1 at 5:42 PM
$DARE What a poor rating of Ovarprene's potential from Bayer. No wonder Dare was tight-lipped about Ovarprene at the latest CC and milestones were absent from their company presentation. There have certainly been talks with Bayer since this summer. The risk in the company has increased. IMO
1 · Reply
GolfPro999
GolfPro999 Dec. 1 at 3:56 PM
$DARE great news today getting the rights back for Ovaprene. 📈 positioned for buyout now.
1 · Reply
UniversalTrading
UniversalTrading Nov. 28 at 12:41 PM
$DARE True .. Shares Ownership - Insiders = 0.97% !! Not even 1% .. Shows you how much they value and believe in their own Company and future doesn't it!! One of the worst Positions I have ever entered. Thank goodness it's only a small Investment! Been here for months and Red since day 1 !! Purely curious as to what f**kery will transpire!!
0 · Reply
zhusjason1
zhusjason1 Nov. 26 at 5:08 PM
$DARE as someone who’s mentioned that insiders never bought this fking 💩 hole , how can it inspire investors to buy more?
0 · Reply
Djdanny
Djdanny Nov. 26 at 3:48 PM
$DARE Unfortunately not here
0 · Reply
Djdanny
Djdanny Nov. 24 at 4:04 PM
$DARE No volume .🤮
0 · Reply
prasan2015
prasan2015 Nov. 24 at 2:08 PM
$DARE could pop here
0 · Reply
prasan2015
prasan2015 Nov. 24 at 2:08 PM
$DARE $$$
0 · Reply
prasan2015
prasan2015 Nov. 24 at 2:02 PM
$DARE $3+++
0 · Reply
HMIC
HMIC Nov. 24 at 1:47 PM
$DARE
0 · Reply
HMIC
HMIC Nov. 24 at 11:09 AM
$DARE Dare to Play compounding begins in December, FDA approval around the corner.
0 · Reply
MyDogKnowsStocks
MyDogKnowsStocks Nov. 21 at 3:17 PM
$DARE For women by women
0 · Reply
Djdanny
Djdanny Nov. 20 at 9:04 PM
$DARE Last hope buyout.
0 · Reply
doodledo77
doodledo77 Nov. 20 at 5:41 PM
$DARE 1 more week for big load here. Anyway a quick one, if you are my follower you might be able to a special oneontj free access to special AI platform soon. Team been busy with it.
0 · Reply
Djdanny
Djdanny Nov. 19 at 9:28 PM
$DARE Market green trash is red.Nothing new..My 3 year worst investment.Cant wait for revenge
0 · Reply
sulljd74
sulljd74 Nov. 19 at 7:55 PM
$DARE damn what a POS
1 · Reply
Djdanny
Djdanny Nov. 19 at 7:31 PM
$DARE CEO needs. step down She sucks .
0 · Reply
Ceri78
Ceri78 Nov. 18 at 8:27 PM
$DARE slowly steady down 🤮
0 · Reply
Bear81
Bear81 Nov. 17 at 6:00 PM
$DARE I would like to remain bullish but one thing makes me hesitant. At these prices why are insiders not buying. I have helped prop up this stock for years. If insiders don't buy they don't believe. I won't buy any more Dare until I see insider purchases.
0 · Reply